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The Rh system is the most complex of the human blood groups. 
Of the 55 antigens that have been characterized, the system’s 
principal antigens D, C, E, c, and e are responsible for the 
majority of clinically significant Rh antibodies. In the last few 
years, advancements in molecular testing have provided a wealth 
of information on the genetic diversity of the Rh locus. This case 
report describes a patient with variant RHD*DAR alleles inherited 
in conjunction with two compound heterozygote RHCE*ceEK/
RHCE*ceAR alleles. The patient was previously alloimmunized to 
D, C, and E and possibly hrS. Further transfusion of D–C–E–K– 
RBCs resulted in a suspected acute hemolytic transfusion reaction 
and the subsequent identification of anti-c. Monocyte monolayer 
assay testing suggests clinical significance with a range of 
29.5–38.5 percent reactive monocytes. Immunohematology 
2018;34:109-112.
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The Rh system is the most complex of the human blood 
groups. Of the 55 antigens that have been characterized, the 
system’s principal antigens D, C, E, c, and e are responsible 
for the majority of clinically significant Rh antibodies. 
Antibodies to antigens in the Rh system have been implicated 
in hemolytic disease of the fetus and newborn (HDFN) as well 
as acute and delayed hemolytic transfusion reactions (HTRs). 
In the last few years, advancements in molecular testing have 
provided a wealth of information on the genetic diversity 
of the Rh locus. The Rh system is a very polymorphic and 
immunogenic blood group system that is second only to the 
ABO system in its clinical significance for blood transfusion. 
Nucleotide changes can result in qualitative and quantitative 
changes in Rh antigen expression.1 Individuals who express 
a partial D on their red blood cells (RBCs) can be immunized 
to make anti-D. Similarly, people who are homozygous or 
hemizygous for alleles encoding partial c and/or partial e 
can also produce alloantibodies.2 In addition to the common 
antigens of the Rh system (D, C, c, E, e) there are 50 additional 
antigens that constitute the Rh blood group system.3 The Rh 
locus consists of a pair of adjacent homologous genes, RHD 
and RHCE, that respectively encode for D and for C or c and 
E or e antithetical pairs. The antigenic diversity present in 
this blood group system is attributed to a variety of molecular 
mechanisms including nucleotide substitutions and gene 
conversion.4 These molecular mechanisms lead to the creation 
of unique protein sequences with resultant unique antigens 
and an increase in the number of antigens in the Rh system 
relative to other blood group systems. Further adding to 
the complexity, variant RHD and RHCE alleles can encode 
qualitative and/or quantitative changes in the Rh antigen 
expression.5 Individuals with such variants, when exposed to 
the conventional antigen during transfusion, will recognize 
those epitopes that they lack as foreign, and an immune 
response may be elicited. Routine serologic RBC phenotyping 
does not differentiate between conventional and variant Rh 
antigens. Within the Rh blood group system, partial D, C, and 
e variants and their corresponding alloantibodies have been 
well described. Alloanti-c in a c+ individual was first reported 
by Moulds et al.6 in 1982, with a number of additional cases 
reported since that time.7–9
Peyrard et al.10 reported the first case of alloanti-c/ce in 
a patient with the RHCE*ceAR allele that encodes a partial 
c antigen. Hipsky et al.11 also described the identification of 
alloanti-c in the plasma of an African American patient with 
sickle cell disease carrying the RHCE*ceAR allele.
We report a case of a 72-year-old multi-transfused 
African American woman with altered RHD and RHCE alleles 
predicting partial D, partial c, and partial e antigens who 
developed a clinically significant alloanti-c.
Case Report
The patient is a 72-year-old African American woman 
with a past medical history of multiple sclerosis, congestive 
heart failure, and recurrent gastrointestinal (GI) bleeding 
secondary to diverticulosis. The patient presented to the 
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Table 1. Molecular testing results
Allele name Antigens encoded by allele
Probable RHD 
genotype





RHCE*ceEK/ Partial c, partial e, Hr–,  
hrS–




Partial D+C–E– partial c+ 
partial e+ Hr– V+w VS– hrS–
emergency department with acute GI bleeding and received 
fluid support and 2 units of packed red blood cells (PRBCs). 
She was admitted to the hospital for further evaluation and 
treatment. A colonoscopy was performed that revealed a 
diverticular bleed in the ascending colon; this bleed was 
successfully cauterized. During this time, her hemoglobin 
(Hgb) was observed to fall to 4.9 g/dL with a hematocrit 
(Hct) of 16 percent (normal 12.0–15.5 g/dL and 37–48%, 
respectively); she was emergently transfused 4 units of PRBCs. 
Initial serologic results indicated the patient to be group A, 
weak D positive with a positive antibody detection test. The 
patient’s previous serologic history included identification of 
anti-D, -C, -E, warm autoantibody, and cold autoantibody. 
The initial antibody screening was performed by the hospital, 
and the presence of additional RBC antibodies was suspected. 
The patient’s sample was referred to the Immunohematology 
Reference Laboratory (IRL) (American Red Cross, 
Charlotte, NC) for further serologic evaluation and antibody 
identification.
Results
Initial serologic testing performed by the IRL indicated 
that the patient was group A, weak D positive with a negative 
direct antiglobulin test (DAT). Serologic phenotype testing 
was performed and the results were C–E–c+e+; K–; Fy(a–b–); 
Jk(a+b+); S+s–. The patient’s plasma exhibited panreactivity 
with D– phenotypically similar RBCs in the presence of a 
negative autocontrol. This reactivity suggested the presence 
of an additional antibody (ies) unrelated to the previously 
identified alloanti-D, -C, and -E. Plasma studies showed 1+ 
reactivity with D– phenotypically similar cells using low-
ionic-strength saline solution in the indirect antiglobulin 
test (IAT) and 3+ reactivity with polyethylene glycol (PEG) 
in the IAT. The reactivity was resistant to ficin treatment as 
well as to 0.2 M dithiothreitol. Given the patient’s history 
of warm and cold autoantibodies, adsorption studies were 
performed at 37°C using ZZAP-treated autologous cells. No 
reduction in strength was observed with the autoadsorbed 
plasma. Allogeneic adsorptions were performed using papain-
treated R0 RBCs. Clinically significant antibodies to common 
RBC blood group antigens were excluded in the alloadsorbed 
plasma. An acid eluate was prepared from the adsorbing cells 
to ascertain the identity of the panreactivity. The acid eluate 
demonstrated an anti-e–like antibody. The eluate was reactive 
with three sources of D– e+ RBCs and negative with three 
sources of D– hrB– RBCs. 
The facility was contacted to report the anti-e–like 
reactivity, and molecular genotype testing was recommended 
for further characterization. No compatible units negative for 
D, C, E, e, and K were available for immediate transfusion. 
Therefore, after consultation with the facility, units negative 
for D, C, E, and K were recommended in the event emergent 
transfusion was needed. 
Unfortunately, there was insufficient time to perform 
a monocyte monolayer assay (MMA) before transfusion of 
incompatible blood.12 An MMA can be performed to help 
assess the clinical significance of an antibody when antigen-
negative units are rare and not likely to be readily available. 
Given the patient’s clinical situation (GI bleed with a low Hgb 
level), the facility transfused 2 crossmatch-incompatible units 
of PRBCs negative for D, C, E, and K over a 48-hour time 
period. No adverse reactions were noted after transfusion of 
e+ units in the presence of the anti-e–like antibody.
Molecular testing was performed by the American Red 
Cross National Molecular Laboratory. Results indicated the 
patient carried a RHD*DAR variant allele inherited with 
compound heterozygote RHCE*ceEK/RHCE*ceAR alleles, 
predicting partial D, partial c, partial e, and the lack of the 
high-prevalence antigens, hrS and Hr (Table 1).
The molecular results confirmed suspected serologic 
reactivity. RHD*DAR allele is associated with D typing 
discrepancies and the production of alloanti-D. In addition, 
the patient had two altered RHCE alleles predicting the hrS– 
phenotype and the production of alloanti-e and/or anti-hrS. 
The facility was contacted to report the additional probable 
anti-hrS reactivity in the presence of previously identified 
anti-D, -C, and -E. Consultation was made with the American 
Rare Donor Program, and no RH allele–matched units were 
available for further transfusion needs. Despite the presence 
of the probable anti-hrS, the patient tolerated the previous 2 
units of PRBCs well, with no adverse effects. The patient’s Hgb 
T.K. Walters and T. Lightfoot
IMMUNOHEMATOLOGY, Volume 34, Number 3, 2018 111
HTR due to anti-c
increased to 7.7 g/dL with an Hct of 23 percent, and she was 
discharged.
Five days after the initial transfusion, the patient was 
readmitted to the hospital for a suspected delayed HTR. 
The patient presented with dark urine, Hgb of 6.3 g/dL, 
total bilirubin of 2.6 mg/dL (normal 0.1–1.2 mg/dL), lactate 
dehydrogenase 1034 IU (normal 100–190 IU), and haptoglobin 
less than 15 mg/dL (normal 30–200 mg/dL). The patient then 
received 2 additional units of D–C–E–K– PRBCs. 
On completion of transfusion of the second unit, the 
patient began to display symptoms of a possible acute HTR. 
The patient’s temperature increased from 98.0 to 99.5°F, with 
accompanying symptoms of rigors, dyspnea, and severe back 
pain. Blood pressure increased from 149/68 mmHg to 166/94 
mmHg, with an increase in pulse from 85 bpm to 93 bpm. 
Oxygen saturation remained unchanged at 99 percent. 
The facility began an initial transfusion reaction 
investigation. The post-transfusion sample was severely 
hemolyzed, but the DAT remained negative. Gram stain 
was performed and was negative for any microorganisms. A 
current blood sample was drawn and sent to the local IRL for 
additional serologic testing. The DAT on both the pre- and 
post-transfusion samples was negative. 
Because of the recent transfusion and suspected 
transfusion reaction, an eluate was prepared despite the 
negative DAT. Expecting the eluate to contain the previously 
identified probable anti-hrS, the eluate was tested against a 
panel of e+ and e– cells. All cells were reactive 4+ at PEG-IAT, 
and the patient’s EDTA glycine acid–treated autologous cells 
were negative, as was the last wash. All cells tested with the 
eluate were positive except for Rhnull RBCs. Two Rhnull RBCs 
were tested and found to be negative with the patient’s neat 
eluate. Additionally, one RBC with the Rh:–46 phenotype was 
available for testing and was significantly weaker in reactivity 
and displayed only a 1+ reaction. This cell was negative for c 
and had a weakened expression of e. Given that the patient’s 
molecular results indicated an altered expression of c, the 
possibility of anti-c or anti-Hr was suspected. The eluate was 
tested against a panel of hrS– cells to investigate the presence of 
anti-Hr, but all cells were 3+ reactive with the neat eluate. The 
eluate was adsorbed using R1R1 cells. Anti-c was demonstrated 
in the adsorbed eluate at PEG-IAT. Additionally, the previously 
identified anti-hrS was also shown to be demonstrating in the 
neat eluate when tested with a c–e+ RBC. 
Plasma studies were also performed on the post-
transfusion sample. The plasma was reactive 4+ with two 
phenotypically similar cells [D–C–E–s–K–Fy(a–b–)]. The 
autocontrol remained negative. Adsorption studies were 
performed using aliquots of R1R1 cells. The adsorbed plasma 
demonstrated the presence of anti-c. To further confirm the 
anti-c specificity, an additional aliquot of the plasma was 
adsorbed with R2R2 cells. An acid eluate was then prepared 
from the adsorption cells. This eluate reacted with D–c+E– 
RBCs and was nonreactive with Rhnull RBCs. Clinically 
significant antibodies to other major blood group antigens 
were excluded in the allogeneic adsorbed eluate and plasma. 
The presence of anti-c in conjunction with anti-D, -C, -E, 
and probable anti-hrS presented significant challenges in the 
possibility of locating any compatible blood for this patient. 
An MMA was performed by the American Red Cross National 
Reference Laboratory for Blood Group Serology in an attempt 
to assess the clinical significance of the alloantibody to the c 
antigen. Two random sources of group O, D–C–E–K– RBCs 
and autogeneic cells were used. Results are listed in Table 2. 
Because the patient had antibodies to both c and e as well as 
to D, C, and E, phenotypically similar cells (D–C–E–) were 
chosen for the MMA. Cells that could further distinguish the 
significance of the reactivity with regard to the partial anti-c 
or probable anti-hrS were not available. MMA testing using 
genotypically similar RBCs would have been ideal, but none 
are currently available in the United States.
Discussion
We report the serologic and molecular findings on a 
72-year-old multi-transfused African American female 
patient. The presence of anti-c in conjunction with anti-D, 
-C, -E, and probable anti-hrS posed significant challenges in 
the identification and provision of compatible blood for this 
patient. The MMA results, the patient’s clinical status, and 
post-transfusion laboratory and serologic results indicate that 
the alloanti-c is clinically significant. 
Table 2. Monocyte monolayer assay results
IgG DAT* % Reactive monocytes†
Random #1 4+ 30.3 with fresh complement
D–C–E–K–Fy(a–b–)s– 4+ 34.0 without fresh complement
Random #2 4+ 38.5 with fresh complement
D–C–E–K– 4+ 29.5 without fresh complement
Autologous cells Negative 0.3 without fresh complement
*Results of coated test red blood cells after 37°C incubation.
†The normal range for the monocyte monolayer assay is 0–3 percent 
reactive monocytes. Values above 3 percent suggest that the antibody may 
cause accelerated clearance of antigen-positive red blood cells.18
DAT = direct antiglobulin test.
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Variants of c are much less frequent than variant forms of 
the other major Rh antigens.12 Westhoff et al.13 postulate that 
the less frequent occurrence of c variants in comparison with 
other Rh antigens is because the two proline residues involved 
in c expression form a stable structure that is resistant to the 
changes that often occur with RHCE. Individuals of African 
descent have a much higher incidence of variant Rh antigens 
as compared with individuals of European descent, with the 
latter constituting the largest percentage of blood donors 
by ethnicity.14,15 The high prevalence of variant antigens 
in African American patients thereby increases the risk of 
alloimmunization when these patients are exposed to the 
conventional antigen during transfusion.16,17 
The detection of the presence of a variant antigen, 
identification of the corresponding alloantibody, determination 
of its clinical significance, and the logistics of finding 
compatible blood can be quite challenging. Rhnull RBCs were 
recommended for any future transfusions for this patient, until 
such time that a possible RH allele–matched donor unit could 
be identified for further compatibility testing and evaluation. 
This case demonstrates the increasingly important role of 
molecular testing in the overall clinical/laboratory assessment 
of alloimmunized patients with partial RBC antigens and for 
subsequent transfusion recommendations and guidance.
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